Impact of Adjuvant Radiation Therapy in Patients With Male Breast Cancer: A Multicenter International Analysis

Daniel Rolf, MD; Khaled Elsayad, MD; Mohamed A.M. Meheissen, MD; Yasser Elkerm, MD; Carl Opitz, MD; Isabel Radke, MD; Anne Bremer, MD; Anne Hülskamp, MD; Rasha Elsaka, MD; Horeya M. Ismail, MD; Essam Elfaham, MD; Abdelsalam Attia Ismail, MD; Hazem Elmansy, MD; Eva Wardelmann, PhD; Amr Abdelaziz Elsaid, MD; Barbara Krause-Bergmann, MD; Joke Tio, MD; Hans Theodor Eich, PhD; Oliver Micke, PhD

Advances in Radiation Oncology (May 2020)

Impact of Adjuvant Radiation Therapy in Patients With Male Breast Cancer: A Multicenter International Analysis

Daniel Rolf, MD,
Khaled Elsayad, MD,
Mohamed A.M. Meheissen, MD,
Yasser Elkerm, MD,
Carl Opitz, MD,
Isabel Radke, MD,
Anne Bremer, MD,
Anne Hülskamp, MD,
Rasha Elsaka, MD,
Horeya M. Ismail, MD,
Essam Elfaham, MD,
Abdelsalam Attia Ismail, MD,
Hazem Elmansy, MD,
Eva Wardelmann, PhD,
Amr Abdelaziz Elsaid, MD,
Barbara Krause-Bergmann, MD,
Joke Tio, MD,
Hans Theodor Eich, PhD,
Oliver Micke, PhD

Affiliations

Daniel Rolf, MD: Department of Radiation Oncology, University Hospital of Münster, Münster, Germany; Corresponding author: Daniel Rolf, MD
Khaled Elsayad, MD: Department of Radiation Oncology, University Hospital of Münster, Münster, Germany
Mohamed A.M. Meheissen, MD: Alexandria Clinical Oncology Department, Alexandria University, Alexandria, Egypt; Specialized Universal Network of Oncology (SUN), Alexandria, Egypt
Yasser Elkerm, MD: Specialized Universal Network of Oncology (SUN), Alexandria, Egypt; Cancer Management and Research Department, Medical Research Institute, Alexandria University, Alexandria, Egypt
Carl Opitz, MD: Department of Gynecology & Obstetrics, University Hospital Münster, Münster, Germany
Isabel Radke, MD: Department of Gynecology & Obstetrics, University Hospital Münster, Münster, Germany
Anne Bremer, MD: Department of Oncology, St. Franziskus-Hospital, Münster, Germany
Anne Hülskamp, MD: Department for Breast Diseases, St. Franziskus-Hospital, Münster, Germany
Rasha Elsaka, MD: Alexandria Clinical Oncology Department, Alexandria University, Alexandria, Egypt; Specialized Universal Network of Oncology (SUN), Alexandria, Egypt
Horeya M. Ismail, MD: Specialized Universal Network of Oncology (SUN), Alexandria, Egypt
Essam Elfaham, MD: Specialized Universal Network of Oncology (SUN), Alexandria, Egypt
Abdelsalam Attia Ismail, MD: Alexandria Clinical Oncology Department, Alexandria University, Alexandria, Egypt; Specialized Universal Network of Oncology (SUN), Alexandria, Egypt
Hazem Elmansy, MD: Specialized Universal Network of Oncology (SUN), Alexandria, Egypt; Cancer Management and Research Department, Medical Research Institute, Alexandria University, Alexandria, Egypt
Eva Wardelmann, PhD: Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
Amr Abdelaziz Elsaid, MD: Alexandria Clinical Oncology Department, Alexandria University, Alexandria, Egypt; Specialized Universal Network of Oncology (SUN), Alexandria, Egypt
Barbara Krause-Bergmann, MD: Department for Breast Diseases, St. Franziskus-Hospital, Münster, Germany
Joke Tio, MD: Department of Gynecology & Obstetrics, University Hospital Münster, Münster, Germany
Hans Theodor Eich, PhD: Department of Radiation Oncology, University Hospital of Münster, Münster, Germany
Oliver Micke, PhD: Department of Radiotherapy and Radiation Oncology, Franziskus Hospital Bielefeld, Bielefeld, Germany

Journal volume & issue: Vol. 5, no. 3
pp. 345 – 349

Abstract

Read online

Purpose: Breast cancer in men accounts for approximately 1% of all breast cancers. Breast cancer trials have routinely excluded men. The aim of this analysis was to determine the effect of different treatment factors, in particular, postoperative radiation therapy (RT) on long-term outcomes. Methods and Materials: Seventy-one patients with male breast cancer treated in 5 closely cooperating institutions between 2003 and 2019 were analyzed. Results: Almost all patients (95%) underwent surgical resection. Forty-two patients (59%) received chemotherapy, and 59 (83%) received adjuvant hormonal therapy. Of the 71 patients, 52 (73%) were treated with RT. The rate of recurrence was 20% in the whole cohort, with a locoregional recurrence rate of 3%. In the entire group, the 5-year local control (LC) was 95%, whereas 5-year progression-free survival (PFS) and 5-year overall survival (OS) were 62% and 96%, respectively. There was a lower rate of relapses after adjuvant RT (19% vs 32%, P = .05) without in-field relapse after postoperative RT (0%) versus 10% in patients without RT (P = .02). In the multivariate analysis performed, hormonal therapy administration was found to have a possible significant effect on LC and PFS. Administration of adjuvant RT and stage affect PFS. In patients who received RT, there were no grade 3 or 4 acute toxicities. Conclusions: Adjuvant RT is an effective and safe treatment for male breast cancer patients with no infield relapses and better PFS. Hormonal therapy administration was found to have a possible effect on LC and PFS.

Published in Advances in Radiation Oncology

ISSN: 2452-1094 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.journals.elsevier.com/advances-in-radiation-oncology/

About the journal